A CCR3 neutralizing monoclonal antibody (mAb) gave similar results (50% inhibition compared with control) and migration was unaffected by a mAb against CCR1, which is not expressed by prostate cancer cells (Fig. 1b,d). The gene discussed is CCR3; the disease is Familial prostate cancer.